AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$CERS

Greenman William Mariner sold $300K of CERS

Greenman William Mariner (President and CEO) sold 101,919 shares of CERUS CORP (CERS) at $2.94 ($0.30M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Greenman William Mariner
Published Jul 2, 2026, 11:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings but does not, by itself, change Cerus’s fundamentals; traders may only adjust short-term sentiment or monitor for future filings.

02

Market read

A disclosed CEO sale (101,919 shares) at $2.9429 on 2026-06-30, filed 2026-07-02, is a sentiment datapoint with limited fundamental implications.

03

What to watch

Insider sales can be misread without context (taxes, diversification, pre-set schedules); the filing lacks any new guidance or performance information.

Relevance 3/10Novelty 4/10Timing: Form 4 filed 2026-07-02 (sale dated 2026-06-30)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Cerus Corp.

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus Corp CEO Greenman William Mariner filed a Form 4 selling 101,919 shares at $2.9429 on 2026-06-30 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational/regulatory/financial catalyst.

Market effects

Sector

Minimal; this is company-specific insider transaction with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    CERUS CORP

    Company whose CEO filed the Form 4 insider sale disclosure.

  • insider
    Greenman William Mariner

    President and CEO; reported an open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min